US Visa Concerns Led ICH To Choose Canadian Meeting Site
Executive Summary
The US, one of ICH’s original three member authorities, was spurned in favor of Canada for the pharmaceutical regulatory harmonization initiative’s next meeting in the region because of some participants’ difficulties obtaining US visas.
You may also be interested in...
Big Pharma Subdued In Its Response To Trump's Travel EO
Big pharma has been muted in its response to President Trump's executive order imposing severe travel restrictions on nationals from seven Muslim-majority countries for 90 days. Small biotech, however, has no reservations about speaking out against the so-called 'immigration ban'.
ICH Reforming in Ways that Could Strengthen Harmonization Process
Twenty-five years after its founding, the organization where the world’s foremost regulatory authorities and industry groups reach agreement on pharmaceutical quality guidelines will incorporate next year in Switzerland. The new Swiss association could strengthen the role of emerging-market authorities in global regulatory harmonization – at least those that meet its membership criteria.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.